Skip to main content
PMC home page
Gut logoLink to Gut
. 2001 Aug;49(2):303–308. doi: 10.1136/gut.49.2.303

Angiotensin converting enzyme inhibitors and angiotensin II antagonists as therapy in chronic liver disease

J VLACHOGIANNAKOS 1, A TANG 1, D PATCH 1, A BURROUGHS 1
PMCID: PMC1728379  PMID: 11454810

Full Text

The Full Text of this article is available as a PDF (162.5 KB).

graphic file with name gut-rrm.f1.jpg

Open in a new tab

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amarapurkar D. N., Dhawan P., Kalro R. H. Role of routine estimation of creatinine clearance in patients with liver cirrhosis. Indian J Gastroenterol. 1994 Jul;13(3):79–82. [PubMed] [Google Scholar]
  2. Armonis A., Patch D., Burroughs A. Hepatic venous pressure measurement: an old test as a new prognostic marker in cirrhosis? Hepatology. 1997 Jan;25(1):245–248. doi: 10.1053/jhep.1997.v25.ajhep0250245. [DOI] [PubMed] [Google Scholar]
  3. Arroyo V., Bosch J., Mauri M., Ribera F., Navarro-López F., Rodés J. Effect of angiotensin-II blockade on systemic and hepatic haemodynamics and on the renin-angiotensin-aldosterone system in cirrhosis with ascites. Eur J Clin Invest. 1981 Jun;11(3):221–229. doi: 10.1111/j.1365-2362.1981.tb01844.x. [DOI] [PubMed] [Google Scholar]
  4. Arroyo V., Bosch J., Mauri M., Viver J., Mas A., Rivera F., Rodes J. Renin, aldosterone and renal haemodynamics in cirrhosis with ascites. Eur J Clin Invest. 1979 Feb;9(1):69–73. doi: 10.1111/j.1365-2362.1979.tb01669.x. [DOI] [PubMed] [Google Scholar]
  5. Atlas S. A., Case D. B., Yu Z. Y., Laragh J. H. Hormonal and metabolic effects of angiotensin converting enzyme inhibitors. Possible differences between enalapril and captopril. Am J Med. 1984 Aug 20;77(2A):13–17. doi: 10.1016/s0002-9343(84)80053-4. [DOI] [PubMed] [Google Scholar]
  6. Bataller R., Ginès P., Nicolás J. M., Görbig M. N., Garcia-Ramallo E., Gasull X., Bosch J., Arroyo V., Rodés J. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology. 2000 Jun;118(6):1149–1156. doi: 10.1016/s0016-5085(00)70368-4. [DOI] [PubMed] [Google Scholar]
  7. Bhathal P. S., Grossman H. J. Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators. J Hepatol. 1985;1(4):325–337. doi: 10.1016/s0168-8278(85)80770-4. [DOI] [PubMed] [Google Scholar]
  8. Brunkhorst R., Wrenger E., Kühn K., Schmidt F. W., Koch K. Effekte einer Captopriltherapie auf die Natrium- und Wasserausscheidung bei Patienten mit Leberzirrhose und Aszites. Klin Wochenschr. 1989 Aug 1;67(15):774–783. doi: 10.1007/BF01745350. [DOI] [PubMed] [Google Scholar]
  9. Burnier M., Brunner H. R. Angiotensin II receptor antagonists. Lancet. 2000 Feb 19;355(9204):637–645. doi: 10.1016/s0140-6736(99)10365-9. [DOI] [PubMed] [Google Scholar]
  10. Chiang H. T., Cheng J. S., Lin M., Tseng W. S., Chang J. M., Lai K. H. Haemodynamic effects of enalaprilat on portal hypertension in patients with HBsAg-positive cirrhosis. J Gastroenterol Hepatol. 1995 May-Jun;10(3):256–260. doi: 10.1111/j.1440-1746.1995.tb01090.x. [DOI] [PubMed] [Google Scholar]
  11. Daskalopoulos G., Pinzani M., Murray N., Hirschberg R., Zipser R. D. Effects of captopril on renal function in patients with cirrhosis and ascites. J Hepatol. 1987 Jun;4(3):330–336. doi: 10.1016/s0168-8278(87)80542-1. [DOI] [PubMed] [Google Scholar]
  12. Eriksson L. S., Kågedal B., Wahren J. Effects of captopril on hepatic venous pressure and blood flow in patients with liver cirrhosis. Am J Med. 1984 May 31;76(5B):66–70. doi: 10.1016/0002-9343(84)90887-8. [DOI] [PubMed] [Google Scholar]
  13. Garcia-Tsao G., Grace N. D., Groszmann R. J., Conn H. O., Bermann M. M., Patrick M. J., Morse S. S., Alberts J. L. Short-term effects of propranolol on portal venous pressure. Hepatology. 1986 Jan-Feb;6(1):101–106. doi: 10.1002/hep.1840060119. [DOI] [PubMed] [Google Scholar]
  14. García-Pagán J. C., Bosch J., Rodés J. The role of vasoactive mediators in portal hypertension. Semin Gastrointest Dis. 1995 Jul;6(3):140–147. [PubMed] [Google Scholar]
  15. García-Tsao G. Angiotensin II receptor antagonists in the pharmacological therapy of portal hypertension: a caution. Gastroenterology. 1999 Sep;117(3):740–742. doi: 10.1016/s0016-5085(99)70472-5. [DOI] [PubMed] [Google Scholar]
  16. Gentilini P., Romanelli R. G., La Villa G., Maggiore Q., Pesciullesi E., Cappelli G., Casini Raggi V., Foschi M., Marra F., Pinzani M. Effects of low-dose captopril on renal hemodynamics and function in patients with cirrhosis of the liver. Gastroenterology. 1993 Feb;104(2):588–594. doi: 10.1016/0016-5085(93)90431-b. [DOI] [PubMed] [Google Scholar]
  17. Girgrah N., Liu P., Collier J., Blendis L., Wong F. Haemodynamic, renal sodium handling, and neurohormonal effects of acute administration of low dose losartan, an angiotensin II receptor antagonist, in preascitic cirrhosis. Gut. 2000 Jan;46(1):114–120. doi: 10.1136/gut.46.1.114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Goa K. L., Wagstaff A. J. Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs. 1996 May;51(5):820–845. doi: 10.2165/00003495-199651050-00008. [DOI] [PubMed] [Google Scholar]
  19. Goodfriend T. L., Elliott M. E., Catt K. J. Angiotensin receptors and their antagonists. N Engl J Med. 1996 Jun 20;334(25):1649–1654. doi: 10.1056/NEJM199606203342507. [DOI] [PubMed] [Google Scholar]
  20. Groszmann R. J., Bosch J., Grace N. D., Conn H. O., Garcia-Tsao G., Navasa M., Alberts J., Rodes J., Fischer R., Bermann M. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology. 1990 Nov;99(5):1401–1407. doi: 10.1016/0016-5085(90)91168-6. [DOI] [PubMed] [Google Scholar]
  21. Hall J. E., Guyton A. C., Jackson T. E., Coleman T. G., Lohmeier T. E., Trippodo N. C. Control of glomerular filtration rate by renin-angiotensin system. Am J Physiol. 1977 Nov;233(5):F366–F372. doi: 10.1152/ajprenal.1977.233.5.F366. [DOI] [PubMed] [Google Scholar]
  22. Helmy A., Jalan R., Newby D. E., Hayes P. C., Webb D. J. Role of angiotensin II in regulation of basal and sympathetically stimulated vascular tone in early and advanced cirrhosis. Gastroenterology. 2000 Mar;118(3):565–572. doi: 10.1016/s0016-5085(00)70263-0. [DOI] [PubMed] [Google Scholar]
  23. Ibarra F. R., Afione C., Garzon D., Barontini M., Santos J. C., Arrizurieta E. Portal pressure, renal function and hormonal profile after acute and chronic captopril treatment in cirrhosis. Eur J Clin Pharmacol. 1992;43(5):477–482. doi: 10.1007/BF02285088. [DOI] [PubMed] [Google Scholar]
  24. Johnston C. I., Clappison B. H., Anderson W. P., Yasujima M. Effect of angiotensin-converting enzyme inhibition on circulating and local kinin levels. Am J Cardiol. 1982 Apr 21;49(6):1401–1404. doi: 10.1016/0002-9149(82)90350-2. [DOI] [PubMed] [Google Scholar]
  25. LARAGH J. H., ANGERS M., KELLY W. G., LIEBERMAN S. Hypotensive agents and pressor substances. The effect of epinephrine, norepinephrine, angiotensin II, and others on the secretory rate of aldosterone in man. JAMA. 1960 Sep 17;174:234–240. doi: 10.1001/jama.1960.03030030014003. [DOI] [PubMed] [Google Scholar]
  26. Lebrec D. Pharmacological treatment of portal hypertension: present and future. J Hepatol. 1998 May;28(5):896–907. doi: 10.1016/s0168-8278(98)80241-9. [DOI] [PubMed] [Google Scholar]
  27. Lebrec D., Poynard T., Bernuau J., Bercoff E., Nouel O., Capron J. P., Poupon R., Bouvry M., Rueff B., Benhamou J. P. A randomized controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a final report. Hepatology. 1984 May-Jun;4(3):355–358. doi: 10.1002/hep.1840040301. [DOI] [PubMed] [Google Scholar]
  28. Marra F. Hepatic stellate cells and the regulation of liver inflammation. J Hepatol. 1999 Dec;31(6):1120–1130. doi: 10.1016/s0168-8278(99)80327-4. [DOI] [PubMed] [Google Scholar]
  29. Nussberger J., Waeber B., Brunner H. R. Clinical pharmacology of ACE inhibition. Cardiology. 1989;76 (Suppl 2):11–22. doi: 10.1159/000174555. [DOI] [PubMed] [Google Scholar]
  30. Ohnishi A., Ishizaki T., Murakami S., Tanaka T. Intrapatient comparison of acute hemodynamic, hormonal, and natriuretic responses to captopril versus enalapril in liver cirrhosis. Clin Pharmacol Ther. 1990 Jul;48(1):67–75. doi: 10.1038/clpt.1990.119. [DOI] [PubMed] [Google Scholar]
  31. Ohnishi A., Murakami S., Harada M., Osaka K., Wada K., Odagiri M., Tsuchiya T., Tanaka T. Renal and hormonal responses to repeated treatment with enalapril in non-azotemic cirrhosis with ascites. J Hepatol. 1994 Feb;20(2):223–230. doi: 10.1016/s0168-8278(05)80062-5. [DOI] [PubMed] [Google Scholar]
  32. Pariente E. A., Bataille C., Bercoff E., Lebrec D. Acute effects of captopril on systemic and renal hemodynamics and on renal function in cirrhotic patients with ascites. Gastroenterology. 1985 May;88(5 Pt 1):1255–1259. doi: 10.1016/s0016-5085(85)80088-3. [DOI] [PubMed] [Google Scholar]
  33. Pinzani M., Failli P., Ruocco C., Casini A., Milani S., Baldi E., Giotti A., Gentilini P. Fat-storing cells as liver-specific pericytes. Spatial dynamics of agonist-stimulated intracellular calcium transients. J Clin Invest. 1992 Aug;90(2):642–646. doi: 10.1172/JCI115905. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Reichen J. Liver function and pharmacological considerations in pathogenesis and treatment of portal hypertension. Hepatology. 1990 Jun;11(6):1066–1078. doi: 10.1002/hep.1840110625. [DOI] [PubMed] [Google Scholar]
  35. Rockey D. C. Vasoactive agents in intrahepatic portal hypertension and fibrogenesis: implications for therapy. Gastroenterology. 2000 Jun;118(6):1261–1265. doi: 10.1016/s0016-5085(00)70379-9. [DOI] [PubMed] [Google Scholar]
  36. Rockey D. C., Weisiger R. A. Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance. Hepatology. 1996 Jul;24(1):233–240. doi: 10.1002/hep.510240137. [DOI] [PubMed] [Google Scholar]
  37. Rockey D. The cellular pathogenesis of portal hypertension: stellate cell contractility, endothelin, and nitric oxide. Hepatology. 1997 Jan;25(1):2–5. doi: 10.1053/jhep.1997.v25.ajhep0250002. [DOI] [PubMed] [Google Scholar]
  38. Schneider A. W., Kalk J. F., Klein C. P. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology. 1999 Feb;29(2):334–339. doi: 10.1002/hep.510290203. [DOI] [PubMed] [Google Scholar]
  39. Schrier R. W., Arroyo V., Bernardi M., Epstein M., Henriksen J. H., Rodés J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988 Sep-Oct;8(5):1151–1157. doi: 10.1002/hep.1840080532. [DOI] [PubMed] [Google Scholar]
  40. Schrier R. W. Renin-angiotensin in preascitic cirrhosis: evidence for primary peripheral arterial vasodilation. Gastroenterology. 1998 Aug;115(2):489–491. doi: 10.1016/s0016-5085(98)70215-x. [DOI] [PubMed] [Google Scholar]
  41. Sims D. E. The pericyte--a review. Tissue Cell. 1986;18(2):153–174. doi: 10.1016/0040-8166(86)90026-1. [DOI] [PubMed] [Google Scholar]
  42. Svoboda P., Ochmann J., Kantorová I. Effect of enalapril treatment and sclerotherapy of esophageal varices on hepatic hemodynamics in portal hypertension. Hepatogastroenterology. 1992 Dec;39(6):549–552. [PubMed] [Google Scholar]
  43. Tsai Y. T., Lin H. C., Lee F. Y., Hou M. C., Wang S. S., Lee S. D. Effects of captopril on renal functions, renal and portal hemodynamics in patients with cirrhosis. Proc Natl Sci Counc Repub China B. 1996 Apr;20(2):44–50. [PubMed] [Google Scholar]
  44. Vlachogiannakos J., Goulis J., Patch D., Burroughs A. K. Review article: primary prophylaxis for portal hypertensive bleeding in cirrhosis. Aliment Pharmacol Ther. 2000 Jul;14(7):851–860. doi: 10.1046/j.1365-2036.2000.00778.x. [DOI] [PubMed] [Google Scholar]
  45. Wong F., Sniderman K., Blendis L. The renal sympathetic and renin-angiotensin response to lower body negative pressure in well-compensated cirrhosis. Gastroenterology. 1998 Aug;115(2):397–405. doi: 10.1016/s0016-5085(98)70206-9. [DOI] [PubMed] [Google Scholar]
  46. Wood L. J., Goergen S., Stockigt J. R., Powell L. W., Dudley F. J. Adverse effects of captopril in treatment of resistant ascites, a state of functional bilateral renal artery stenosis. Lancet. 1985 Nov 2;2(8462):1008–1009. doi: 10.1016/s0140-6736(85)90551-3. [DOI] [PubMed] [Google Scholar]
  47. Yoo K. H., Thornhill B. A., Wolstenholme J. T., Chevalier R. L. Tissue-specific regulation of growth factors and clusterin by angiotensin II. Am J Hypertens. 1998 Jun;11(6 Pt 1):715–722. doi: 10.1016/s0895-7061(98)00018-1. [DOI] [PubMed] [Google Scholar]
  48. van Vliet A. A., Hackeng W. H., Donker A. J., Meuwissen S. G. Efficacy of low-dose captopril in addition to furosemide and spironolactone in patients with decompensated liver disease during blunted diuresis. J Hepatol. 1992 May;15(1-2):40–47. doi: 10.1016/0168-8278(92)90009-e. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES